

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1 fu

U.S. SERIAL NO. : 10/566,625
APPLICANTS : Klaus, et al.
FILING DATE : 30 January 2006
GROUP ART UNIT : Unassigned
EXAMINER : Unassigned
DOCKET NO. : FP0617 US
TITLE : INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS
GAMMA GLOBIN INDUCERS

Commissioner for Patents
PO Box 1451
Alexandria VA 22313-1450

TRANSMITTAL

The following items accompany this Transmittal:

1. Return Receipt Postcard (1pg)
2. IDS (2pgs)(in dup)
3. SB/08A (2pgs)
4. Copy of Int'l Search Report (5pgs)
5. References (6)

Please call Applicants' representative at 650.866.7265 with any questions regarding this communication or the above-referenced application. The Commissioner is hereby authorized to charge any necessary fees to **Deposit Account No. 50-0811**. **This form is enclosed in duplicate.**

Applicants claim small entity status under 37 C.F.R. 1.27.

Respectfully submitted,

Date: 9 March 2006

By: Christopher Turner
Christopher Turner, Ph.D.
Reg. No. 45,167

FIBROGEN, INC.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650.866.7200
Direct: 650.866.7265
Facsimile: 650.866.7292

Certificate of mailing or transmission under 37 CFR § 1.8


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 9 March 2006.

Name: Michael Moores Signature: Michael Moores

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **9** March, 2006 by Michael Moores.

Signed: _____



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

S. Serial No. : 10/566,625
Applicants : Klaus, et al.
Filing Date : 30 January 2006
Group Art Unit : Unassigned
Examiner : Unassigned
Docket No. : FP0617 US
Title : INHIBITORS OF 2-OXOGLUTARATE DIOXYGENASE AS GAMMA
GLOBIN INDUCERS

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.97(b)**

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97, and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "Information Disclosure Statement By Applicant" (Form PTO/SB/08A). Applicants reserve the right to antedate any reference in accordance with standard procedure.

The documents were cited in an International Search Report established by the European Patent Office (ISA/EP) in international application number PCT/US2004/024916. A copy of the International Search Report is enclosed. Any non-patent cited reference is also enclosed.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the present application. In addition, this submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI or other report included on the attached list may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be


attached to the markings. Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Form PTO/SB/08A be returned to Applicants.

If there are any questions regarding this communication, please call the undersigned at 650-866-7200.


Applicants believe that no fee is due in this communication. If, however, the Commissioner determines that a fee is due, authorization is hereby given to charge the total of any such fee to Deposit Account No. 50-0811, referencing Docket No. FP0617 US. This form is enclosed in duplicate.

Respectfully submitted,
FibroGen, Inc.

DATE: 8 March 2006


Christopher Turner, Ph.D.
Reg. No. 45,167

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco CA 94080
Main: 650-866-7200
Direct: 650-866-7254
Facsimile: 650-866-7204



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	FP0617 US

Sheet	1	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	WO-97/12855-A1	10 Apr 1997	Vertex Pharmaceuticals		
	BB	WO-03/053997-A2	03 Jul 2003	FibroGen, Inc.		
	BC	WO-2004/004697-A2	15 Jan 2004	Univ Degli Studi di Ferrara		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/566,625
Filing Date	30 January 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	FP0617 US

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	DOVER, George J., "Induction of Fetal Hemoglobin Production in Subjects with Sickle Cell Anemia by Oral Sodium Phenylbutyrate," Blood, W.B. Saunders, Philadelphia, PA. U.S., 7/1/1994, Vol. 84, No. 1, pgs. 339-343	
	CB	PERRINE, Susan P., et al., "Sodium Butyrate Enhances Fetal Globin Gene Expression in Erythroid Progenitors of Patients with Hb SS and Beta Thalassemia," Blood, W.B. Saunders, Philadelphia, PA. U.S., 7/1/89, Vol. 74, No. 1, pgs. 454-459	
	CC	RODGERS, Griffin P., et al., "Novel Treatment Options in the Severe Beta-Globin Disorders," British Journal of Haematology, Oxford, Great Britain, 1995, Vol. 91, No. 2, pgs. 263-268	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.